CliffBio
biologic

Nexobrid

anacaulase-bcdb

Loss of exclusivityDecember 2034projected — 12-year biologic exclusivity estimate
CompanyVericel Corporation →See this company's full patent-cliff portfolio

Drug detail

Brand nameNexobrid
Active ingredientanacaulase-bcdb
Strength8.8% (4.85GM)
Dosage formFor Topical Gel
RouteTopical
ModalityBiologic
FDA approvalDecember 2022
Marketing statusRx

More from Vericel Corporation

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Nexobrid patent cliff — loss of exclusivity December 2034 | CliffBio